Inpharma

Antihypertensives not only beneficial in hypertension
pp. 2-2(1)

The pros and cons of Rx-to-OTC switching of drugs in the US
pp. 3-3(1)

Inadequate flu vaccination coverage among patients with CV disorders
pp. 3-3(1)

Amantadine "consistently cost saving" among healthy US workers
pp. 3-3(1)

Switch from IV to oral quinolones cost saving for Spanish hospital
pp. 4-4(1)

CBT "feasible alternative" to antidepressants in the UK
pp. 4-4(1)

Celecoxib most cost-effective choice in high-risk arthritis patients
pp. 4-4(1)

Clarithromycin, amoxicillin/clavulanic acid in acute sinusitis
pp. 5-5(1)

Mifepristone + misoprostol good cost option for medical abortion
pp. 5-5(1)

Apaziquone may induce a response in patients with superficial bladder cancer
pp. 5-5(1)

VNP 40101M may induce a response in AML, MDS
pp. 5-5(1)

More R&D news from the 12th CROI
pp. 6-7(2)

Leflunomide may reduce viral load in patients with polyomavirus type BK nephropathy
pp. 8-8(1)

Pioglitazone may be effective for the treatment of psoriatic arthritis
pp. 8-8(1)

Zanolimumab: prolonged responses in mycosis fungoides
pp. 8-8(1)

SGN 00101 [HspE7] may be effective in cervical dysplasia
pp. 8-8(1)

The insulin sensitiser metaglidasen reduces glycosylated haemoglobin levels (HbA1c) in patients with type 2 diabetes mellitus
pp. 8-8(1)

Long-term treatment with ketoconazole is effective for patients with familial male-limited precocious puberty
pp. 9-9(1)

Tamoxifen plus RT: sequencing not vital in breast cancer
pp. 9-9(1)

The combination of PT 141 and sildenafil has an additive effect on erectile dysfunction
pp. 9-9(1)

Adalimumab in it for the long haul in psoriasis
pp. 11-11(1)

Clofarabine induces a response in adult patients with acute myeloid leukaemia, and in paediatric patients with acute lymphoblastic leukaemia
pp. 11-11(1)

Childhood vaccination reduces mortality in melanoma
pp. 12-12(1)

Fluticasone propionate "not effective" in wheezy infants
pp. 12-12(1)

A tocopherol a day keeps ALS at bay?
pp. 12-12(1)

Modafinil augmentation improves response to SSRIs in MDD
pp. 12-12(1)

Infliximab makes an impact in psoriatic arthritis
pp. 13-14(2)

Daclizumab + tacrolimus a feasible corticosteroid-free regimen
pp. 14-14(1)

Pemetrexed + either carboplatin or oxaliplatin for advanced NSCLC
pp. 15-15(1)

IFN- prevents hepatocellular carcinoma in HCV + cirrhosis
pp. 15-15(1)

Pneumococcal vaccine immunogenic in paediatric patients with HIV
pp. 15-15(1)

Vardenafil improves sexual quality of life (QOL) in both men with erectile dysfunction and their partners
pp. 15-15(1)

Clopidogrel + eptifibatide CLEARs PLATELETS after coronary stenting
pp. 16-16(1)

Lopinavir/ritonavir + nevirapine maintains viral suppression
pp. 16-16(1)

Carboplatin + gemcitabine has the edge in NSCLC
pp. 16-16(1)

Nifedipine GITS reduces the combined incidence of all-cause mortality and cardiovascular events in comorbid stable angina and hypertension
pp. 16-16(1)

Clopidogrel adds further protection in STEMI
pp. 17-18(2)

Furosemide is beneficial for patients with severe, but not mild, pre-eclampsia
pp. 19-19(1)

Cinacalcet keeps calcium on par in primary hyperparathyroidism
pp. 19-19(1)

Tamoxifen metabolite affected by CYP2D6 polymorphism, inhibitors
pp. 19-19(1)

Doxazosin improves sexual dysfunction in patients with BPH
pp. 19-19(1)

Tibolone associated with increased endometrial cancer risk?
pp. 20-20(1)

Losartan reduces muscle sympathetic nerve activity and increases cardiac baroreceptor sensitivity in patients with mild-to-medium hypertension
pp. 20-20(1)

Reports of influenza virus vaccine-related adverse events (AEs) in infants increased
pp. 20-20(1)

Risperidone reduces the severity of tardive dyskinesia
pp. 20-20(1)

A possible increase in HF risk: is all HOPE lost for tocopherol?
pp. 21-21(1)

EU product approvals
pp. 21-21(1)

US product launches
pp. 21-21(1)

Product approvals in Japan
pp. 22-22(1)

US product approvals
pp. 22-22(1)

Other US regulatory news
pp. 22-22(1)

Eli Lilly has launched three analogue formulations of insulin in Japan
pp. 22-22(1)

The Chinese State Food and Drug Administration has issued Sinovac Biotech a New Drug Certificate approving its split influenza vaccine
pp. 22-22(1)

Pitavastatin [Pitava; Zydus Cadila] has been launched in India
pp. 22-22(1)

OSI Pharmaceuticals' erlotinib [Tarceva] has been approved in Switzerland for the treatment of non-small-cell lung cancer
pp. 22-22(1)

Product Introductions
pp. 23-23(1)